Royalty Pharma (RPRX) Holds Firm After Pelacarsen Setback, Is The Stock Fully Priced?

Royalty Pharma (RPRX) is back in focus after Novartis reported that the Phase 3 HORIZON outcomes trial for pelacarsen did not meet its primary cardiovascular endpoint in patients with elevated lipoprotein(a).

Despite the pelacarsen setback, Royalty Pharma’s short term share price momentum has been firm, with a 7 day share price return of 5.11% and a 30 day return of 10.75%. The 1 year total shareholder return of 80.76% and 3 year total shareholder return of 136.55% point to strong longer term gains that frame today’s US$63.96 share price and recent news in the context of an already solid run.

Spot opportunities that echo Royalty Pharma’s mix of downside protection and upside potential by scanning our hand picked 82 resilient stocks with low risk scores with resilient fundamentals and measured risk profiles.

Royalty Pharma has rerated hard, yet the share price still only sits a touch below analyst targets while implying a far larger discount to some fair value estimates. How wide is that gap once the numbers are lined up?

Most Popular Narrative: 120% Undervalued

The most followed narrative on Royalty Pharma pegs fair value at $64.75, which sits only slightly above the $63.96 last close yet assumes a much richer long term earnings profile than today’s price implies.

Strategic reinvestment of large, stable cash flows into new and increasingly innovative royalty acquisitions, enhanced by improved data-driven diligence and risk management, allows Royalty Pharma to continually expand its portfolio with attractive economics, increasing operating leverage and net margins over time.

Read the complete narrative. Read the complete narrative.

Want to see what is driving that valuation gap for Royalty Pharma? The narrative leans heavily on faster revenue compounding, fatter margins and a richer profit multiple. Curious which assumptions matter most and how they stack up against today’s earnings base.

Result: Fair Value of $64.75 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Royalty Pharma’s story can change quickly if the Alyftrek royalty dispute or pressures on key blockbuster royalties reduce cash flows more than analysts currently factor in.

Find out about the key risks to this Royalty Pharma narrative.

Another View on Royalty Pharma’s Valuation

The earlier fair value narrative for Royalty Pharma leans on future earnings and cash flow strength. The current P/E of 35.1x tells a very different story. It is higher than the estimated fair ratio of 25.6x, the US Pharmaceuticals industry at 16.3x, and peers at 25.9x. That gap points to meaningful valuation risk if sentiment cools. The question for investors is which signal to rely on more in their own assessment.

For a closer look at what the numbers imply for valuation risk around Royalty Pharma, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment on Royalty Pharma clearly mixed, it helps to look past the headlines and check the data for yourself, including its 2 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Royalty Pharma?

If you stop at Royalty Pharma, you could miss other opportunities that fit your style. Put the same discipline to work by scanning a few focused stock ideas.

• Target potential mispricing by checking a curated group of companies that screen as attractively valued through our 47 high quality undervalued stocks.
• Strengthen the income side of your portfolio by reviewing companies that offer robust yields in the 11 dividend fortresses.
• Prioritise resilience by filtering for financially sturdy businesses using the list of solid balance sheet and fundamentals (52 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com